A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia
Latest Information Update: 08 Jul 2025
At a glance
- Drugs ELVN-001 (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; First in man; Proof of concept
- Acronyms CML; ENABLE
- Sponsors Enliven Therapeutics
Most Recent Events
- 03 Jul 2025 Planned number of patients changed from 180 to 200.
- 13 Jun 2025 Result (n=53) presented in the Enliven Therapeutics Media Release
- 13 Jun 2025 According to an Enliven Therapeutics media release, company presented positive data from the Phase 1 ENABLE clinical trial in an oral presentation at the European Hematology Association (EHA) 2025 Congress taking place June 12-15 in Milan, Italy, and virtually.